Farxiga Pediatric (Under 12) Dosing: What Clinicians and Parents Should Know

Dapagliflozin Has No FDA-Approved Pediatric Dose for Children Under 12

There is no FDA-approved dose of dapagliflozin for any patient younger than 18, and no clinical trial has published dosing data for children under 12. The current Farxiga prescribing information states explicitly that safety and efficacy have not been established in pediatric patients for its approved indications: type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction, and chronic kidney disease [1].

AstraZeneca's pediatric study obligations under the Pediatric Research Equity Act (PREA) have focused on adolescents aged 10 and older, not younger children. The FDA's pediatric study decision letter for dapagliflozin did not require trials in children below age 10 because type 2 diabetes prevalence in that group remains very low. A 2017 analysis published in Pediatrics estimated that fewer than 1 in 10 to 000 U.S. children aged 5 to 9 carried a type 2 diabetes diagnosis [2].

This absence of data is not a gap that clinicians should attempt to fill through extrapolation from adult dosing. SGLT2 inhibitors produce their glucose-lowering effect by blocking renal glucose reabsorption, causing obligate glycosuria of approximately 50 to 80 grams of glucose per day in adults. In a 25-kg child, that caloric loss represents a proportionally larger metabolic burden, with unknown effects on linear growth and pubertal development.

How Dapagliflozin Works and Why Pediatric Pharmacology Differs

Dapagliflozin blocks the SGLT2 transporter in the proximal renal tubule, preventing roughly 30 to 50% of filtered glucose from being reabsorbed back into the bloodstream. The excess glucose is excreted in urine. In adults with type 2 diabetes, a 10 mg daily dose reduces HbA1c by approximately 0.5 to 0.7 percentage points and produces modest weight loss of 2 to 3 kg over 24 weeks [3].

Pediatric pharmacokinetics differ from adult profiles in ways that matter for SGLT2 inhibitors specifically. Children have higher glomerular filtration rates relative to body surface area than adults, meaning more glucose is filtered and potentially more is lost in urine per kilogram of body weight. Renal tubular maturation continues through childhood. The SGLT2 transporter density in a 6-year-old kidney has not been characterized in published human tissue studies.

These unknowns make simple weight-based dose scaling unreliable. A 30-kg child given a "half adult dose" of 5 mg could experience disproportionate glycosuria, volume depletion, or electrolyte shifts compared to what a 70-kg adult experiences at the same dose. The American Academy of Pediatrics has not endorsed SGLT2 inhibitor use in any child under 10.

What the Adult Evidence Shows (and Why It Does Not Transfer to Young Children)

The landmark DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) in adults with heart failure and reduced ejection fraction [4]. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [5].

These results reshaped adult cardiology and nephrology practice. They did not, however, include any participants younger than 18. The median age in DAPA-HF was 66 years. The youngest enrolled patients were in their early twenties.

Extrapolating heart failure or CKD trial results to a child under 12 involves at least three unsupported assumptions: that the pathophysiology is comparable, that the drug's distribution and metabolism are similar, and that the benefit-risk ratio holds in a developing body. None of these have been tested.

The DELIVER trial extended dapagliflozin's heart failure benefit to patients with preserved ejection fraction (HFpEF), but the minimum enrollment age was 40 years [6]. Pediatric heart failure is predominantly congenital or cardiomyopathic in origin, a fundamentally different disease biology than the ischemic and hypertensive etiologies dominating adult trials.

Pediatric Trials in Progress: Adolescents Only

AstraZeneca has registered studies evaluating dapagliflozin in adolescents aged 10 to 17 with type 2 diabetes. These trials use a starting dose of 5 mg daily with possible titration to 10 mg, mirroring the adult dosing protocol. No published results from these studies are available as of May 2026.

The ClinicalTrials.gov registry lists NCT03429543 as a phase 3 study of dapagliflozin in pediatric patients aged 10 to less than 18 years with type 2 diabetes. The study's primary endpoint is change in HbA1c at 26 weeks. Enrollment criteria explicitly exclude children under 10 [7].

This trial design reflects a practical reality. Type 2 diabetes in children under 10 is rare enough that powering a randomized trial would require enrollment across dozens of sites over many years. The SEARCH for Diabetes in Youth study found that incidence of type 2 diabetes in U.S. youth aged 10 to 19 increased by 4.8% per year between 2002 and 2012, but the vast majority of cases occurred in adolescents aged 12 and older [8].

For heart failure and CKD in children, no SGLT2 inhibitor trials of any kind have been completed. The pediatric nephrology community has expressed interest in studying these agents for conditions like focal segmental glomerulosclerosis and Alport syndrome, but formal trial protocols have not been published.

Safety Risks Unique to Younger Children

The safety profile of dapagliflozin in adults includes well-characterized risks that take on different dimensions in growing children. These concerns are not theoretical. They reflect known pharmacologic effects extrapolated to a population with active development.

Genital mycotic infections occur in 5 to 7% of adult women and 2 to 3% of adult men taking SGLT2 inhibitors, driven by glucosuria creating a favorable environment for Candida overgrowth [9]. In prepubertal children, genital skin is thinner and the local microbiome less established. A higher susceptibility to vulvovaginal or balanitis infections is plausible but unstudied.

Volume depletion and electrolyte disturbance present a greater risk in smaller bodies with lower total blood volume. A 25-kg child has an estimated blood volume of roughly 1.75 liters. The osmotic diuresis produced by dapagliflozin, which causes approximately 375 mL of additional urine output per day in adults, represents a proportionally larger fluid shift in a small child [10].

Euglycemic diabetic ketoacidosis (DKA) is a recognized class effect of SGLT2 inhibitors. The FDA issued a safety communication warning about this risk in 2015 [11]. Children, who have lower glycogen reserves and higher metabolic rates per kilogram, may be more susceptible to ketosis during periods of reduced oral intake, such as during common childhood illnesses.

Bone health is another concern. Dapagliflozin increases phosphate reabsorption and raises serum phosphorus levels modestly. In adults this shift is clinically insignificant, but in children undergoing active skeletal mineralization, even small perturbations in calcium-phosphate homeostasis could theoretically affect bone density accrual. The Endocrine Society's clinical guidelines on pediatric bone health emphasize the vulnerability of the growing skeleton to metabolic disruptions [12].

Caloric wasting is perhaps the most concerning theoretical risk. If a child excretes 50 grams of glucose daily, that represents 200 kcal lost, roughly 10 to 15% of total daily energy needs for a 6-year-old. Over months to years, this caloric drain could impair weight gain and linear growth. No study has assessed this.

What the ADA and Endocrine Society Recommend for Pediatric Type 2 Diabetes

The American Diabetes Association (ADA) Standards of Care 2025 recommend metformin and insulin as the only pharmacologic agents with sufficient evidence for use in youth with type 2 diabetes [13]. The ADA's pediatric chapter acknowledges the growing interest in GLP-1 receptor agonists and SGLT2 inhibitors for adolescents but does not recommend their use in children under 10.

Liraglutide (Victoza) received FDA approval for type 2 diabetes in children aged 10 and older in 2019, making it the first non-insulin injectable approved for this group. That approval was based on the ELLIPSE trial, which enrolled 135 participants aged 10 to 17 and showed a 0.64 percentage point HbA1c reduction compared to placebo [14].

No SGLT2 inhibitor has achieved a comparable milestone. The 2023 Endocrine Society position statement on pediatric obesity and type 2 diabetes lists SGLT2 inhibitors as agents requiring further pediatric data before clinical use can be recommended [15].

The practical implication: a clinician caring for a child under 12 with type 2 diabetes should use metformin as first-line therapy, add insulin if glycemic targets are not met, and consider liraglutide for patients aged 10 and older if additional therapy is needed. Dapagliflozin does not appear in any evidence-based pediatric treatment algorithm.

Off-Label Use: Legal but Not Advisable Without Specialized Oversight

Physicians in the United States can legally prescribe any FDA-approved drug off-label, including to children. This legal authority does not equate to clinical endorsement. Off-label prescribing of dapagliflozin to a child under 12 would occur in the absence of any published pharmacokinetic, efficacy, or safety data for that age group.

If a pediatric endocrinologist or nephrologist determines that the potential benefit justifies the unknown risk, such prescribing should occur only under the following conditions as outlined by the American Academy of Pediatrics Committee on Drugs: documented informed consent specifying the off-label nature, a clear rationale in the medical record, a monitoring protocol for known class-effect adverse events, and regular reassessment of growth parameters [16].

"The absence of a pediatric label does not mean a drug is dangerous for children, but it does mean we are flying without instruments," noted Dr. Robert Ward, former chair of the AAP Committee on Drugs, in a 2014 Pediatrics commentary on off-label drug use in children [16].

In practice, insurance coverage for off-label pediatric dapagliflozin use is typically denied. A 30-day supply of brand-name Farxiga carries a list price of approximately $580 as of 2026. Generic dapagliflozin became available in the U.S. in late 2025, reducing cost to approximately $30 to $80 per month depending on pharmacy, but prior authorization denials remain common for non-approved age groups.

Monitoring Requirements If Dapagliflozin Is Used Off-Label in a Child

No published pediatric monitoring protocol exists for dapagliflozin. The following framework is extrapolated from adult labeling, class-effect safety data, and pediatric pharmacovigilance principles. It should not replace individualized specialist guidance.

Baseline testing before initiation would reasonably include: serum creatinine with estimated GFR, serum electrolytes (sodium, potassium, bicarbonate, phosphorus, calcium), HbA1c, urinalysis, blood ketone level (beta-hydroxybutyrate), and a complete growth assessment including height velocity, weight, and Tanner staging.

During treatment, monitoring every 4 to 6 weeks for the first 3 months, then every 3 months, should include: renal function, electrolytes, urinalysis for infection and ketones, blood ketones if symptomatic, and growth parameters plotted on CDC growth charts. Any decline in height velocity or unexpected weight loss should prompt immediate reassessment and possible discontinuation.

The FDA's label for Farxiga recommends checking renal function before starting and periodically thereafter in adults. In children, more frequent monitoring is warranted given the developmental unknowns [1].

Parents should be educated about signs of volume depletion (reduced urine output, dizziness, dry mouth), genital infection (itching, redness, discharge), and ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing, fruity breath odor). Sick-day rules should be established at initiation: hold dapagliflozin during any illness causing reduced oral intake, fever above 38.5°C, or vomiting.

The Bottom Line for Clinicians and Families

No evidence supports dapagliflozin use in children under 12. The FDA has not approved it, clinical trials have not studied it, and professional societies have not recommended it for this age group. Metformin remains first-line for pediatric type 2 diabetes, with insulin and liraglutide (age 10 and older) as established add-on options per ADA 2025 Standards of Care [13]. Any off-label use of dapagliflozin below age 12 should occur only under direct pediatric subspecialist supervision with documented informed consent and an intensive monitoring plan that includes growth velocity tracking at every visit.